231 related articles for article (PubMed ID: 8262050)
1. Transcription activation by Myc and Max: flanking sequences target activation to a subset of CACGTG motifs in vivo.
Fisher F; Crouch DH; Jayaraman PS; Clark W; Gillespie DA; Goding CR
EMBO J; 1993 Dec; 12(13):5075-82. PubMed ID: 8262050
[TBL] [Abstract][Full Text] [Related]
2. Gene-regulatory properties of Myc helix-loop-helix/leucine zipper mutants: Max-dependent DNA binding and transcriptional activation in yeast correlates with transforming capacity.
Crouch DH; Fisher F; Clark W; Jayaraman PS; Goding CR; Gillespie DA
Oncogene; 1993 Jul; 8(7):1849-55. PubMed ID: 8510929
[TBL] [Abstract][Full Text] [Related]
3. Mga, a dual-specificity transcription factor that interacts with Max and contains a T-domain DNA-binding motif.
Hurlin PJ; Steingrìmsson E; Copeland NG; Jenkins NA; Eisenman RN
EMBO J; 1999 Dec; 18(24):7019-28. PubMed ID: 10601024
[TBL] [Abstract][Full Text] [Related]
4. Myc-Max heterodimers activate a DEAD box gene and interact with multiple E box-related sites in vivo.
Grandori C; Mac J; Siëbelt F; Ayer DE; Eisenman RN
EMBO J; 1996 Aug; 15(16):4344-57. PubMed ID: 8861962
[TBL] [Abstract][Full Text] [Related]
5. The NMR solution structure of a mutant of the Max b/HLH/LZ free of DNA: insights into the specific and reversible DNA binding mechanism of dimeric transcription factors.
Sauvé S; Tremblay L; Lavigne P
J Mol Biol; 2004 Sep; 342(3):813-32. PubMed ID: 15342239
[TBL] [Abstract][Full Text] [Related]
6. Design and properties of a Myc derivative that efficiently homodimerizes.
Soucek L; Helmer-Citterich M; Sacco A; Jucker R; Cesareni G; Nasi S
Oncogene; 1998 Nov; 17(19):2463-72. PubMed ID: 9824157
[TBL] [Abstract][Full Text] [Related]
7. Rox, a novel bHLHZip protein expressed in quiescent cells that heterodimerizes with Max, binds a non-canonical E box and acts as a transcriptional repressor.
Meroni G; Reymond A; Alcalay M; Borsani G; Tanigami A; Tonlorenzi R; Lo Nigro C; Messali S; Zollo M; Ledbetter DH; Brent R; Ballabio A; Carrozzo R
EMBO J; 1997 May; 16(10):2892-906. PubMed ID: 9184233
[TBL] [Abstract][Full Text] [Related]
8. Analysis of the Myc and Max interaction specificity with lambda repressor-HLH domain fusions.
Marchetti A; Abril-Marti M; Illi B; Cesareni G; Nasi S
J Mol Biol; 1995 May; 248(3):541-50. PubMed ID: 7752223
[TBL] [Abstract][Full Text] [Related]
9. Mmip1: a novel leucine zipper protein that reverses the suppressive effects of Mad family members on c-myc.
Gupta K; Anand G; Yin X; Grove L; Prochownik EV
Oncogene; 1998 Mar; 16(9):1149-59. PubMed ID: 9528857
[TBL] [Abstract][Full Text] [Related]
10. Mnt, a novel Max-interacting protein is coexpressed with Myc in proliferating cells and mediates repression at Myc binding sites.
Hurlin PJ; Quéva C; Eisenman RN
Genes Dev; 1997 Jan; 11(1):44-58. PubMed ID: 9000049
[TBL] [Abstract][Full Text] [Related]
11. MondoA, a novel basic helix-loop-helix-leucine zipper transcriptional activator that constitutes a positive branch of a max-like network.
Billin AN; Eilers AL; Coulter KL; Logan JS; Ayer DE
Mol Cell Biol; 2000 Dec; 20(23):8845-54. PubMed ID: 11073985
[TBL] [Abstract][Full Text] [Related]
12. Transcriptional activation by the human c-Myc oncoprotein in yeast requires interaction with Max.
Amati B; Dalton S; Brooks MW; Littlewood TD; Evan GI; Land H
Nature; 1992 Oct; 359(6394):423-6. PubMed ID: 1406955
[TBL] [Abstract][Full Text] [Related]
13. Distinct DNA binding preferences for the c-Myc/Max and Max/Max dimers.
Solomon DL; Amati B; Land H
Nucleic Acids Res; 1993 Nov; 21(23):5372-6. PubMed ID: 8265351
[TBL] [Abstract][Full Text] [Related]
14. Sin3 corepressor function in Myc-induced transcription and transformation.
Harper SE; Qiu Y; Sharp PA
Proc Natl Acad Sci U S A; 1996 Aug; 93(16):8536-40. PubMed ID: 8710905
[TBL] [Abstract][Full Text] [Related]
15. Specificity of DNA binding of the c-Myc/Max and ARNT/ARNT dimers at the CACGTG recognition site.
Swanson HI; Yang JH
Nucleic Acids Res; 1999 Aug; 27(15):3205-12. PubMed ID: 10454619
[TBL] [Abstract][Full Text] [Related]
16. Transcriptional activities of the Myc and Max proteins in mammalian cells.
Kretzner L; Blackwood EM; Eisenman RN
Curr Top Microbiol Immunol; 1992; 182():435-43. PubMed ID: 1490382
[TBL] [Abstract][Full Text] [Related]
17. Mad3 and Mad4: novel Max-interacting transcriptional repressors that suppress c-myc dependent transformation and are expressed during neural and epidermal differentiation.
Hurlin PJ; Quéva C; Koskinen PJ; Steingrímsson E; Ayer DE; Copeland NG; Jenkins NA; Eisenman RN
EMBO J; 1995 Nov; 14(22):5646-59. PubMed ID: 8521822
[TBL] [Abstract][Full Text] [Related]
18. Oncogenic activity of the c-Myc protein requires dimerization with Max.
Amati B; Brooks MW; Levy N; Littlewood TD; Evan GI; Land H
Cell; 1993 Jan; 72(2):233-45. PubMed ID: 8425220
[TBL] [Abstract][Full Text] [Related]
19. The alternatively initiated c-Myc proteins differentially regulate transcription through a noncanonical DNA-binding site.
Hann SR; Dixit M; Sears RC; Sealy L
Genes Dev; 1994 Oct; 8(20):2441-52. PubMed ID: 7958908
[TBL] [Abstract][Full Text] [Related]
20. Insights into the mechanism of heterodimerization from the 1H-NMR solution structure of the c-Myc-Max heterodimeric leucine zipper.
Lavigne P; Crump MP; Gagné SM; Hodges RS; Kay CM; Sykes BD
J Mol Biol; 1998 Aug; 281(1):165-81. PubMed ID: 9680483
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
